IRAK Inhibitor Design for Selective Kinase Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases and conditions related to interleukin receptor-associated kinase (IRAK) lack effective kinase inhibitors that can specifically target IRAK1, IRAK2, IRAK3, and IRAK4, leading to inadequate management of auto-immune diseases, inflammatory disorders, and other conditions.
Innovation Solution
Development of compounds with specific formulas that act as kinase inhibitors, particularly targeting IRAK proteins, formulated as pharmaceutical compositions that can be administered to inhibit IRAK activity, thereby treating associated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for IRAK-related diseases, then treatment is provided, but the treatments lack effective kinase inhibitors that can specifically target IRAK1, IRAK2, IRAK3, and IRAK4
Solution Approach 1:
The patent develops kinase inhibitors with specific molecular structures (Formula 1 compounds) that are tailored to bind to specific IRAK kinase active sites. The local chemical properties of the inhibitor molecules are optimized to match the specific binding pockets of IRAK1, IRAK2, IRAK3, and IRAK4, enabling selective inhibition of these targets while sparing other kinases.
Solution Approach 2:
The patent employs structure-activity relationship (SAR) optimization to systematically modify molecular parameters of the kinase inhibitors. By changing substituent groups, linker lengths, and core structures in the Formula 1 compounds, the invention optimizes binding affinity and selectivity for IRAK kinases, transforming general kinase inhibitors into specific IRAK-targeted agents.
2Reliability
If broad-spectrum kinase inhibitors are used, then kinase activity is inhibited, but specificity to IRAK proteins is reduced
Solution Approach 1:
The Formula 1 kinase inhibitors contain specific functional groups and structural features that are localized to interact with unique residues in the IRAK kinase binding pocket. This local structural optimization ensures that the inhibitors maintain strong binding to IRAK proteins while minimizing off-target effects on other kinase families.
3Measurement precision
If new kinase inhibitors are developed to specifically target IRAK proteins, then treatment precision is improved, but drug development complexity increases
Solution Approach 1:
The patent develops a series of Formula 1 compounds with a common core structure that can target multiple IRAK kinases (IRAK1, IRAK2, IRAK3, IRAK4) simultaneously. This multi-functional approach allows a single lead compound to provide broad IRAK coverage, reducing the need to develop separate inhibitors for each kinase and thereby simplifying the overall drug development program.
Data Source
AI summary
Disclosed embodiments concern kinase inhibitors, such as interleukin receptor associated kinases (IRAK) inhibitors according to Formula 1, and compositions comprising such inhibitors.Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent a kinase-associated disease or condition, particularly an IRAK-associated disease or condition.